Tamoxifen. A treatment for meningioma?

•In the setting of breast cancer, two studies showed that tamoxifen reduces the risk of meningioma.•Tamoxifen treatment duration strongly correlated cumulative given dose.•However, meningioma related progression-free survival was not modified by tamoxifen.•Overall survival was not prolonged under prolonged tamoxifen treatment. No large-scale study evaluating the usefulness of tamoxifen after meningioma surgery has been undertaken. We processed the French Système National des Données de Santé (SNDS) database using an algorithm combining the type of surgical procedure and the International Classification of Diseases to retrieve cases of meningiomas operated between 2007 and 2017. Survival analyses were performed using a matched cohort study. 251 patients treated by tamoxifen were extracted from a nationwide population-based cohort of 28 924 patients operated on for a meningioma over a 10-year period. 94% were female and median age at meningioma first surgery was 57 years IQR[47–67]. Tamoxifen treatment median duration was 1.4 years IQR[0.4–3.2]. Tamoxifen treatment median cumulative given dose was 11.4 gs, IQR[3.6–24.9]. There was a strong positive correlation between treatment duration and cumulative dose (τ=0.81, p